TEL AVIV, Israel and BETHESDA, Maryland, Nov. 28, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office.
The patent covers the Company’s novel drug targeting technology accustomed to deliver cannabinoid compounds. Utilizing magnetic delivery system, this innovative non-invasive approach allows external and internal systemic delivery of cannabinoids to the actual area of tumors within the patient.
Dr. Eyal Ballan, Co-Founder and CTO, said: “Our positive primary results showing antitumor properties of cannabis urged us to develop a targeting ability of cannabinoids to tumors and create higher concentration of active compounds around the tumor. Personalization and Targeting are in the forefront of cancer medicine and applying them to the therapeutic potential of cannabis is our ongoing concern.”
About Cannabics Pharmaceuticals
Headquartered in Tel-Aviv, Israel, Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals and LinkedIn.
For more information about Cannabics visit www.Cannabics.com